Source: http://www.google.com/patents/US8148424?dq=7,669,134
Timestamp: 2016-10-28 05:29:28
Document Index: 32494919

Matched Legal Cases: ['Application No. 01909008', 'Application No. 2001236805', 'Application No. 61553', 'Application No. 2', 'Application No. 2', 'Application No. 2', 'Application No. 2', 'Application No. 2', 'Application No. 01807536', 'Application No. 200510003855', 'Application No. 99812829', 'Application No. 01', 'Application No. 01', 'Application No. 01', 'Application No. 99', 'Application No. 99', 'Application No. 99', 'Application No. 2000', 'Application No. 2000', 'Application No. 2000', 'Application No. 2001', 'Application No. 10', 'Application No. 10', 'Application No. 10', 'Application No. 510732', 'Application No. 510732', 'Application No. 520798', 'Application No. 520798', 'Application No. 2001111019', 'Application No. 2001111019', 'Application No. 2002124135', 'Application No. 88120073', 'Application No. 88120073', 'Application No. 88120073', 'Application No. 88120073', 'Application No. 2001236805', 'Application No. 61553', 'Application No. 2', 'Application No. 2', 'Application No. 2', 'Application No. 2', 'Application No. 2', 'Application No. 01', 'Application No. 01', 'Application No. 01', 'Application No. 99', 'Application No. 99', 'Application No. 99', 'Application No. 2000', 'Application No. 2000', 'Application No. 510732', 'Application No. 510732', 'Application No. 2001111019', 'Application No. 99', 'Application No. 99']

Patent US8148424 - Tocopherols, tocotrienols, other chroman and side chain derivatives and uses ... - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inPatentsThe present invention provides an antiproliferative compound having a structural formula where X and Y independently are oxygen, nitrogen or sulfur; R1 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, carboxylic acid, carboxylate, carboxamide, ester, thioamide, thiolacid, thiolester, saccharide, alkoxy-linked...http://www.google.com/patents/US8148424?utm_source=gb-gplus-sharePatent US8148424 - Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereofAdvanced Patent SearchTry the new Google Patents, with machine-classified Google Scholar results, and Japanese and South Korean patents.Publication numberUS8148424 B2Publication typeGrantApplication numberUS 12/771,439Publication dateApr 3, 2012Filing dateApr 30, 2010Priority dateSep 23, 1998Fee statusPaidAlso published asUS6703384, US7300954, US7718814, US8664264, US20020107207, US20040097431, US20080161349, US20100303899, US20120251616, WO2003039461A2, WO2003039461A3Publication number12771439, 771439, US 8148424 B2, US 8148424B2, US-B2-8148424, US8148424 B2, US8148424B2InventorsBob G. Sanders, Kimberly Kline, Weiping YuOriginal AssigneeResearch Development FoundationExport CitationBiBTeX, EndNote, RefManPatent Citations (73), Non-Patent Citations (150), Classifications (20), Legal Events (1) External Links: USPTO, USPTO Assignment, EspacenetTocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS3869477Jan 30, 1973Mar 4, 1975Kowa Yakuhin Kogyo Kabushiki KTocopheryl-p-chlorophenoxyisobutyric acid esterUS4181725May 2, 1977Jan 1, 1980The Regents Of The University Of MichiganMethod for alleviating psoriasisUS4320141Dec 14, 1978Mar 16, 1982Yasuhiro KomatsuAntitumor agentUS4457918May 12, 1982Jul 3, 1984The General Hospital CorporationGlycosides of vitamins A, E and KUS4617317Oct 31, 1984Oct 14, 1986Bennet Justin DMethod of treating ulcerative colitisUS4645845Mar 12, 1984Feb 24, 1987Basf AktiengesellschaftNovel optically active chroman derivatives, their preparation and novel intermediatesUS4665204Jun 27, 1985May 12, 1987Henkel CorporationDiester derivatives of tocopherolUS4873088Jul 13, 1987Oct 10, 1989Liposome Technology, Inc.Liposome drug delivery method and compositionUS4895719Mar 6, 1987Jan 23, 1990Liposome Technology, Inc.Method and apparatus for administering dehydrated liposomes by inhalationUS5114957May 8, 1990May 19, 1992Biodor U.S. HoldingTocopherol-based antiviral agents and method of using sameUS5135945Jun 5, 1991Aug 4, 1992Merrell Dow Pharmaceuticals Inc.Cholesterol-lowering tocopherol analogsUS5260294May 27, 1992Nov 9, 1993Hoffman-La Roche Inc.Chromanes and their pharmaceutical compositions and methodsUS5315017May 1, 1992May 24, 1994Adir Et CompagnieBenzopyran compoundsUS5336485Mar 10, 1993Aug 9, 1994Center For Innovative TechnologyMethod for protecting animals against tacrine induced cytotoxic injury using sterol compoundsUS5393775Sep 7, 1993Feb 28, 1995Adir Et CompagnieBenzopyran compoundsUS5403834Dec 7, 1992Apr 4, 1995Eukarion, Inc.Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of diseaseUS5480645Dec 29, 1993Jan 2, 1996Lifegroup S.P.A.Hydroxyamines N-acyl derivatives having scavenger activity and useful in acute and chronic pathologies associated with peroxidation and inflammation phenomenaUS5545660Mar 12, 1993Aug 13, 1996Merrell Pharmaceuticals Inc.Hydrazide derivatives of 3,4-dihydro-2H-1-benzopyransUS5610180Aug 8, 1994Mar 11, 1997Virginia Commonwealth UniversityIonizable congeners of aromatic and aliphatic alcohols as anti-leukemia agentsUS5650404Jul 18, 1995Jul 22, 1997Senju Pharmaceutical Co., Ltd.Therapeutic composition for pancreatitisUS5747162Feb 7, 1997May 5, 1998Ppg Industries, Inc.Substrates coated with antioxidant compositions and method for inhibiting the oxidation of such compositions applied to a substrateUS5780445Feb 2, 1996Jul 14, 1998Beiersdorf AgTocopheryl glycosides, their preparation, and their use as surfactants, as antioxidants and as the active substance preventing cell ageing in cosmetic or pharmaceutical preparationsUS5827878Jun 27, 1997Oct 27, 1998Nisshin Flour Milling Co., Ltd.Pharmaceutical composition for the treatment of leukemia containing 9-cis-retinoic acid-α-tocopherol esterUS5915818Apr 18, 1997Jun 29, 1999Nikon CorporationImage input apparatusUS5917060Dec 17, 1997Jun 29, 1999Basf AktiengesellschaftPreparation of chromanyl derivativesUS5919818Dec 16, 1997Jul 6, 1999Lipogenics, Inc.Tocotrienols and tocotrienol-like compounds and methods for their useUS5990322Mar 9, 1999Nov 23, 1999Sk CorporationAlpha-tocopherol cyclopropylates, the new vitamin E derivatives and method for producing the sameUS6022560Jun 8, 1998Feb 8, 2000Clarion Pharmaceuticals Inc.Pharmaceutical compositions, novel uses, and novel form of α-tocopherylphosphocholineUS6127382Aug 16, 1999Oct 3, 2000Allergan Sales, Inc.Amines substituted with a tetrahydroquinolinyl group an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activityUS6133312Feb 23, 1998Oct 17, 2000Wisconsin Alumni Research FoundationMethod of suppressing tumor growth with combinations of isoprenoids and statinsUS6417223Sep 23, 1999Jul 9, 2002Research Development FoundationTocopherols, tocotrienols, other chroman and side chain derivatives and uses therofUS6645998Apr 12, 2002Nov 11, 2003Research Development FoundationTocopherols, tocotrienols, other chroman and side chain derivatives and uses thereofUS6770672Feb 11, 2000Aug 3, 2004Research Development FoundationTocopherols, tocotrienols, other chroman and side chain derivatives and uses thereofUS7045324Apr 21, 2003May 16, 2006Research Development FoundationTocopherol associated protein and uses thereofUS7300954Oct 28, 2003Nov 27, 2007Research Development FoundationTocopherols, tocotrienols, other chroman and side chain derivatives and uses thereofUS7312232Aug 20, 2003Dec 25, 2007Research Development FoundationTocopherols, tocotrienols, other chroman and side chain derivatives and uses thereofUS20030236301Dec 19, 2002Dec 25, 2003Bob SandersLiposomal delivery of vitamin E based compoundsCS172015B1 Title not availableDE4304303A1Feb 12, 1993Aug 18, 1994Pacific Chem Co LtdVitamin E derivatives containing a quaternary nitrogen atomEP0436911A2Dec 21, 1990Jul 17, 1991Eisai Co., Ltd.Novel vitamin E derivatives and process for the production thereofEP0506048A1Mar 26, 1992Sep 30, 1992Dainippon Ink And Chemicals, Inc.Sulfated tocopheryl oligosaccharides and antiviral agents including the same as active ingredientsEP0636618A1Apr 16, 1992Feb 1, 1995Marigen S.A.Spontaneously dispersible concentrates and microemulsions with vitamin E compounds for the preparation of medicaments with anti-tumour activityEP0751125A1Jun 17, 1996Jan 2, 1997Basf AktiengesellschaftEsters and amides of 9 (Z)-retinoic acidEP0754458A1Jul 13, 1996Jan 22, 1997Senju Pharmaceutical Co., Ltd.Antiallergic composition comprising a phosphoric diester compoundEP0768314A1Oct 10, 1996Apr 16, 1997Senju Pharmaceutical Co., Ltd.Ascorbic acid tocopheryl phosphate diestersFR2672601A1 Title not availableJP2000128865A Title not availableJP2002526446A Title not availableJPH065519A Title not availableJPH0912538A Title not availableJPH01211578A Title not availableJPH02149577A Title not availableJPH04229269A Title not availableJPH05148292A Title not availableJPH06502185A Title not availableJPH07138159A Title not availableJPH07508982A Title not availableJPH09301953A Title not availableJPH09301969A Title not availableJPS5484034A Title not availableJPS5573690A Title not availableJPS5576871A Title not availableJPS6441727A Title not availableJPS57175186A Title not availableJPS59157085A Title not availableJPS63303049A Title not availableWO1996018609A1Nov 30, 1995Jun 20, 1996Procept, Inc.Formation and utility of sulfonic acid protecting groupsWO1997041852A1May 8, 1997Nov 13, 1997Alcon Laboratories, Inc.Angiostatic compoundsWO1998017246A1Oct 21, 1997Apr 30, 1998RocUse of complexes for the preparation of compositions for the treatment of sensitive skin, preparation process and hypoallergenic compositionsWO1999024417A1Nov 5, 1998May 20, 1999Mcgill UniversityAnalogs of vitamin eWO2000016772A1Sep 23, 1999Mar 30, 2000Research Development FoundationTocopherols, tocotrienols, other chroman and side chain derivatives and uses thereofWO2001058889A1Feb 9, 2001Aug 16, 2001Research Development FoundationTocopherols, tocotrienols, other chroman and side chain derivatives and uses thereofWO2003039461A2Nov 1, 2002May 15, 2003Research Development FoundationTocopherols, tocotrienols, other chroman and side chain derivatives and uses thereofNon-Patent CitationsReference1"The Merck Manual of Diagnosis and Therapy," Merck Research Laboratories, edited by Beers and Berkow, pp. 397, 398, 948, 949, 1127-1135; 1999.2Arya et al., "Design and synthesis of analogs of vitamin E: antiproliferative activity against human breast adenocarcinoma cells," Bioorg. Med. Chem. Lett., 8:2433-2438, 1998.3Balis, "Evolution of anticancer drug discovery and the role of cell-based screening," J. Natl. Cancer Inst., 94:78-79, 2002.4Bidzila et al., "Solubilization of alpha-Tocopherol and its analogs in aqueous solutions of nonionic surfactant," Colloid Journal, 57(2):173-175, 1995.5Brown et al., "Novel heteroarotinoids as potential antagonists of mycobacterium bovis BCG," J. Med. Chem., 47:1008-1017, 2004.6Burke et al., "Effects of topical and oral vitamin E on pigmentation and skin cancer induced by ultraviolet irradiation in Skh:2 hairless mice," Nutrition and Cancer, 38(1):87-97, 2000.7Denny et al., "Potential antitumor agents. 36. Quantitative relationships between experimental antitumor activity, toxicity, and structure for the general class of 9-anilinoacridine antitumor agents," Journal of Medicinal Chemistry, 25(3):276-315, 1982.8Djuric et al., "Growth inhibition of MCF-7 and MCF-10A human breast cells by alpha-tocopheryl hemisuccinate, cholesteryl hemisuccinate and their ether analogs," Cancer Lett., 111:133-139, 1997.9Dominguez, "Hydroxyacetophenone derivatives from B. glutinosa," J. Nat. Prod., 49:143-144, 1986.10European Search Report issued in European Patent Application No. 01909008.3, dated Mar. 10, 2003.11Fabiani et al., "Antioxidants prevent the lymphocyte DNA damage induced by PMA-stimulated monocytes," Nutrition and Cancer, 39(2):284-291, 2001.12Fariss et al., "The selective antiproliferative effects of alpha-tocopheryl hemisuccinate and cholesteryl hemisuccinate on murine leukemia cells result from the action of the intact compounds," Cancer Res., 54:3346-3351, 1994.13Fatope et al., "Design, synthesis, and testing of potential antisickling agents," J. Med. Chem., 30:1973-1977, 1987.14Gura, "Systems for identifying new drugs are often faulty," Science, New Series, 278:1041-1042, 1997.15Helzlsouer et al., "Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer," J Nat Cancer Inst, 92(24):2018-2023, 2000.16Helzlsouer et al., "Association between α-tocopherol, γ-tocopherol, selenium, and subsequent prostate cancer," J Nat Cancer Inst, 92(24):2018-2023, 2000.17Jiang et al., "gamma-tocopherol, the major form of vitamin E in the US diet, deserves more attention," Am J Clin Nutr, 74:714-722, 2001.18Jiang et al., "γ-tocopherol, the major form of vitamin E in the US diet, deserves more attention," Am J Clin Nutr, 74:714-722, 2001.19Kakizaki et al., "Effect of a alpha-tocopherol on hepatocarcinogenesis in transforming growth factor-alpha (TGF-alpha) transgenic mice treated with diethylnitrosamine," Int J Vitam Nutr Res, 71(5):261-267, 2001.20Kakizaki et al., "Effect of a α-tocopherol on hepatocarcinogenesis in transforming growth factor-α (TGF-α) transgenic mice treated with diethylnitrosamine," Int J Vitam Nutr Res, 71(5):261-267, 2001.21Kerbel, "What is the optimal rodent model for anti-tumor drug testing?" Cancer and Metastasis, 17:301-304, 1999.22Koga and Terao, "Antioxidant behaviors of vitamin E analogues in unilamellar vesicles," Biosci. Biotech. Biochem., 60(6):1043-1045, 1996.23Koga et al., "Antioxidant behaviors of vitamin E analogues in unilamellar vscicles," Biosci. Biotech. Biochem., 60(6):1043-1045, 1996.24Koyama et al., "Synthesis of fluorine analogues of vitamin E. II. Synthesis of 2-(3-chloropropyl)-2,5,7,8-tetramethyl-6-chromanol and its application for stereocontrolled Wittig reaction with trifluoromethyl ketones," Chem. Pharm. Bull., 36:2950-2954, 1988.25Malvy et al., "Effect of two years' supplementation with natural antioxidants on vitamin and trace elements status biomarkers: preliminary data of the SU.VI.MAX study," Cancer Detection and Prevention, 25(5):479-485, 2001.26Monks et al., "The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets," Anti-Cancer Drug Design, 12:553-541, 1997.27Neuzil et al., "Vitamin E analogues as inducers of apoptosis: implications for their potential antineoplastic role," Redox Report, 6(3):143-151, 2001.28Notice of Allowance issued in U.S. Appl. No. 09/404,001, dated Feb. 19, 2002.29Notice of Allowance issued in U.S. Appl. No. 09/502,592, dated Jun. 2, 2003.30Notice of Allowance issued in U.S. Appl. No. 10/008,066, dated Sep. 8, 2003.31Notice of Allowance issued in U.S. Appl. No. 10/122,019, dated Jun. 5, 2003.32Notice of Allowance issued in U.S. Appl. No. 10/644,418, dated Aug. 10, 2007.33Notice of Allowance issued in U.S. Appl. No. 10/695,275, dated Jul. 26, 2007.34Notice of Allowance issued in U.S. Appl. No. 11/876,612, dated Apr. 10, 2009.35Notice of Allowance issued in U.S. Appl. No. 11/928,991, dated Dec. 28, 2009.36Office Communication issued in Australian Patent Application No. 2001236805, dated Feb. 8, 2005.37Office Communication issued in Australian Patent Application No. 61553/99, dated Jul. 19, 2002.38Office Communication issued in Canadian Patent Application No. 2,345,079, dated Jan. 15, 2010.39Office Communication issued in Canadian Patent Application No. 2,345,079, dated Jan. 19, 2009.40Office Communication issued in Canadian Patent Application No. 2,345,079, dated Nov. 15, 2007.41Office Communication issued in Canadian Patent Application No. 2,345,079, dated Sep. 30, 2010.42Office Communication issued in Canadian Patent Application No. 2,399,802, dated Jan. 24, 2008.43Office Communication issued in Chinese Patent Application No. 01807536.3, dated Feb. 4, 2005.44Office Communication issued in Chinese Patent Application No. 200510003855.0, dated Jun. 30, 2006.45Office Communication issued in Chinese Patent Application No. 99812829.5, dated Apr. 4, 2003.46Office Communication issued in European Patent Application No. 01 909 008.3, dated Apr. 7, 2006.47Office Communication issued in European Patent Application No. 01 909 008.3, dated Feb. 20, 2007.48Office Communication issued in European Patent Application No. 01 909 008.3, dated Mar. 11, 2005.49Office Communication issued in European Patent Application No. 99 948 352.2, dated Jan. 23, 2008.50Office Communication issued in European Patent Application No. 99 948 352.2, dated Mar. 2, 2009.51Office Communication issued in European Patent Application No. 99 948 352.2, dated Sep. 28, 2006.52Office Communication issued in Japanese Patent Application No. 2000-573733, dated Dec. 15, 2009.53Office Communication issued in Japanese Patent Application No. 2000-573733, dated Jun. 28, 2011.54Office Communication issued in Japanese Patent Application No. 2000-573733, dated Sep. 28, 2010.55Office Communication issued in Japanese Patent Application No. 2001-558439, dated Apr. 19, 2011.56Office Communication issued in Korean Patent Application No. 10-2001-7003703, dated May 29, 2006.57Office Communication issued in Korean Patent Application No. 10-2002-7010387, dated Aug. 17, 2007.58Office Communication issued in Korean Patent Application No. 10-2002-7010387, dated Jan. 29, 2007.59Office Communication issued in New Zealand Patent Application No. 510732, dated Apr. 16, 2002.60Office Communication issued in New Zealand Patent Application No. 510732, dated Jan. 15, 2003.61Office Communication issued in New Zealand Patent Application No. 520798, dated Apr. 1, 2004.62Office Communication issued in New Zealand Patent Application No. 520798, dated Nov. 11, 2003.63Office Communication issued in Russian Patent Application No. 2001111019, dated Jul. 14, 2003.64Office Communication issued in Russian Patent Application No. 2001111019, dated Sep. 29, 2003.65Office Communication issued in Russian Patent Application No. 2002124135, dated Nov. 26, 2004.66Office Communication issued in Taiwanese Patent Application No. 88120073, dated Dec. 19, 2002.67Office Communication issued in Taiwanese Patent Application No. 88120073, dated Feb. 20, 2001.68Office Communication issued in Taiwanese Patent Application No. 88120073, dated Jul. 23, 2002.69Office Communication issued in Taiwanese Patent Application No. 88120073, dated Oct. 25, 2001.70Office Communication issued in U.S. Appl. No. 09/404,001, dated Nov. 27, 2000.71Office Communication issued in U.S. Appl. No. 09/502,592, dated Feb. 12, 2002.72Office Communication issued in U.S. Appl. No. 10/644,418, dated Jan. 11, 2006.73Office Communication issued in U.S. Appl. No. 10/644,418, dated Mar. 22, 2007.74Office Communication issued in U.S. Appl. No. 10/644,418, dated Nov. 1, 2006.75Office Communication, issued in U.S. Appl. No. 09/404,001, dated Aug. 9, 2001.76Office Communication, issued in U.S. Appl. No. 09/404,001, dated Feb. 21, 2001.77Office Communication, issued in U.S. Appl. No. 09/404,001, dated Jan. 23, 2002.78Office Communication, issued in U.S. Appl. No. 09/404,001, dated Oct. 29, 2001.79Office Communication, issued in U.S. Appl. No. 09/502,592, dated Jul. 30, 2002.80Office Communication, issued in U.S. Appl. No. 10/008,066, dated Jul. 29, 2003.81Office Communication, issued in U.S. Appl. No. 10/008,066, dated May 12, 2003.82Office Communication, issued in U.S. Appl. No. 10/695,275, dated Aug. 1, 2006.83Office Communication, issued in U.S. Appl. No. 10/695,275, dated Dec. 16, 2004.84Office Communication, issued in U.S. Appl. No. 10/695,275, dated Jan. 24, 2007.85Office Communication, issued in U.S. Appl. No. 10/695,275, dated Jun. 1, 2005.86Office Communication, issued in U.S. Appl. No. 10/695,275, dated Mar. 6, 2006.87Office Communication, issued in U.S. Appl. No. 10/695,275, dated Sep. 10, 2004.88Office Communication, issued in U.S. Appl. No. 11/876,612, dated Apr. 10, 2009.89Office Communication, issued in U.S. Appl. No. 11/876,612, mailed Aug. 1, 2008.90Office Communication, issued in U.S. Appl. No. 11/928,991, dated Mar. 24, 2009.91Office Communication, issued in U.S. Appl. No. 11/928,991, dated Oct. 14, 2009.92Panthanaickal et al., "Structure-activity relationships in antibumor aniline mustards," Journal of Medicinal Chemistry, 21(1):16-26, 1978.93PCT International Preliminary Examination Report issued in International Application No. PCT/US01/04168, dated Sep. 15, 2003.94PCT International Preliminary Examination Report issued in International Application No. PCT/US99/21778, dated Jan. 24, 2001.95PCT International Search Report issued in International Application No. PCT/US01/04168, dated May 23, 2001.96PCT International Search Report issued in International Application No. PCT/US02/35147, dated Sep. 12, 2003.97PCT International Search Report issued in International Application No. PCT/US99/21778, dated Feb. 4, 2000.98PCT Written Opinion issued in International Application No. PCT/US02/35147, dated Nov. 18, 2004.99PCT Written Opinion issued in International Application No. PCT/US99/21778, dated Sep. 7, 2000.100Prasad et al., "Effects of tocopherol (vitamin E) acid succinate on morphological alterations and growth inhibition in melanoma cells in culture," Cancer Res., 42:550-555, 1982.101Response to Office Communication submitted in Australian Patent Application No. 2001236805, dated Jun. 24, 2005.102Response to Office Communication submitted in Australian Patent Application No. 61553/99, dated Nov. 26, 2002.103Response to Office Communication submitted in Canadian Patent Application No. 2,345,079, dated Jul. 12, 1010.104Response to Office Communication submitted in Canadian Patent Application No. 2,345,079, dated Jul. 14, 2009.105Response to Office Communication submitted in Canadian Patent Application No. 2,345,079, dated May 15, 2008.106Response to Office Communication submitted in Canadian Patent Application No. 2,345,079, dated Nov. 3, 2010.107Response to Office Communication submitted in Canadian Patent Application No. 2,399,802, dated Jul. 24, 2008.108Response to Office Communication submitted in European Patent Application No. 01 909 008.3, dated Jan. 19, 2007.109Response to Office Communication submitted in European Patent Application No. 01 909 008.3, dated Jun. 20, 2007.110Response to Office Communication submitted in European Patent Application No. 01 909 008.3, dated Oct. 18, 2005.111Response to Office Communication submitted in European Patent Application No. 99 948 352.2, dated Feb. 8, 2007.112Response to Office Communication submitted in European Patent Application No. 99 948 352.2, dated Jul. 23, 2008.113Response to Office Communication submitted in European Patent Application No. 99 948 352.2, dated Jun. 17, 2009.114Response to Office Communication submitted in Japanese Patent Application No. 2000-573733, dated Mar. 25, 2011.115Response to Office Communication submitted in Japanese Patent Application No. 2000-573733, dated May 31, 2010.116Response to Office Communication submitted in New Zealand Patent Application No. 510732, dated Nov. 26, 2002.117Response to Office Communication submitted in New Zealand Patent Application No. 510732, dated Oct. 13, 2002.118Response to Office Communication submitted in Russian Patent Application No. 2001111019, dated Sep. 16, 2003.119Response to Office Communication submitted in U.S. Appl. No. 09/404,001, dated Aug. 30, 2001.120Response to Office Communication submitted in U.S. Appl. No. 09/404,001, dated Dec. 19, 2000.121Response to Office Communication submitted in U.S. Appl. No. 09/404,001, dated Feb. 5, 2002.122Response to Office Communication submitted in U.S. Appl. No. 09/502,592, dated Jul. 3, 2003.123Response to Office Communication submitted in U.S. Appl. No. 09/502,592, dated Mar. 6, 2002.124Response to Office Communication submitted in U.S. Appl. No. 10/008,066, dated Aug. 19, 2003.125Response to Office Communication submitted in U.S. Appl. No. 10/008,066, dated Jun. 5, 2003.126Response to Office Communication submitted in U.S. Appl. No. 10/644,418, dated Aug. 16, 2006.127Response to Office Communication submitted in U.S. Appl. No. 10/644,418, dated Feb. 1, 2007.128Response to Office Communication submitted in U.S. Appl. No. 10/644,418, dated Jun. 12, 2006.129Response to Office Communication submitted in U.S. Appl. No. 10/644,418, dated Jun. 12, 2007.130Response to Office Communication submitted in U.S. Appl. No. 10/695,275, dated Apr. 24, 2007.131Response to Office Communication submitted in U.S. Appl. No. 10/695,275, dated Jun. 23, 2006.132Response to Office Communication submitted in U.S. Appl. No. 10/695,275, dated Mar. 3, 2005.133Response to Office Communication submitted in U.S. Appl. No. 10/695,275, dated Nov. 28, 2005.134Response to Office Communication submitted in U.S. Appl. No. 10/695,275, dated Sep. 24, 2004.135Response to Office Communication submitted in U.S. Appl. No. 11/928,991, dated Jun. 24, 2009.136Response to Office Communication submitted in U.S. Appl. No. 11/928,991, dated Nov. 16, 2009.137Response to Office Communication, issued in U.S. Appl. No. 11/876,612, submitted Dec. 21, 2008.138Response to PCT Written Opinion submitted in International Application No. PCT/US99/21778, dated Nov. 13, 2000.139Schwartz, "Directed lysis of experimental cancer by beta-carotene in liposomes," Nutrition and Cancer, 16:107-124, 1991.140Schwartz, "The administration of beta carotene to prevent and regress oral carcinoma in the hamster cheek pouch and the associated enhancement of the immune response," Adv Exp Med Biol, 262:77-93, 1990.141Schwartz, "The effect of cartenoids on the antitumor immune response tin vivo and invitro with hamster and mouse immune effectors," Annals New York Academy of Sciences, 587:92-109, 1990.142Schwartz, "Directed lysis of experimental cancer by β-carotene in liposomes," Nutrition and Cancer, 16:107-124, 1991.143Supplementary European Search Report issued in European Patent Application No. 99 948 352.2, dated Sep. 2, 2002.144Supplementary Partial European Search Report issued in European Patent Application No. 99 948 352.2, dated Jun. 21, 2002.145Takara et al., "Water-soluble prodrug of vitamin E for parenteral use and its effect on endotoxin-induced liver toxicity," Biological & Pharmaceutical Bulletin, 20(2):204-209, 1997.146Urano et al., "Synthesis of dl-alpha-tocopherol and dl-alpha-tocotrienol," Chem. Pharm. Bull., 31:4341-4345, 1983.147Urano et al., "Synthesis of dl-α-tocopherol and dl-α-tocotrienol," Chem. Pharm. Bull., 31:4341-4345, 1983.148Welch et al., "Syntheses and activities of antioxidant derivatives of retinoic acids," J. Med. Chem., 25:81-84, 1982.149Werninghaus et al., "Protective effect of alpha-tocopherol in carrier liposomes on ultraviolet-mediated human epidermal cell damage in vitro," Photodermatol Photoimmunol Photomed, 8(6):236-242, 1991.150Will et al., "Attachment of vitamin E derivatives to oligonucleotides during solid-phase synthesis," Tetrahedron Lett. 33:2729-2732, 1992.Classifications U.S. Classification514/456, 549/408, 549/416, 514/458International ClassificationA01N43/16, C07D311/66, C07D311/58, C07D311/72, C07D215/46, C07D215/20Cooperative ClassificationC07D311/72, C07D311/58, C07D215/46, C07D311/66, C07D215/20European ClassificationC07D311/66, C07D311/58, C07D311/72, C07D215/46, C07D215/20Legal EventsDateCodeEventDescriptionSep 16, 2015FPAYFee paymentYear of fee payment: 4RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services